2021 Q4 IngenioRx Drug and Biologic Pipeline

January 18, 2022 | Download PDF

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming FDA approvals. This newsletter analyzes drugs and biologics in development. Open the attachment to learn about:

Emerging therapies for the treatment of vasomotor symptoms associated with menopause, severe asthma, and hypertrophic cardiomyopathy.

Evaluate significant product approvals, including biosimilars expected in 2021 and 2022.

Offer insights on the current gene therapy pipeline.

The latest on psoriasis and migraine pipelines.